Celltrion is rapidly expanding its influence in the Oceania market, including Australia and New Zealand, by sharply increasing its market share in breast cancer and autoimmune disease treatments.
According to pharmaceutical market research firm IQVIA, the biosimilar Herzuma, used for breast cancer and gastric cancer treatment, recorded a 56% market share in Australia as of the third quarter of 2025. In the Australian market where six trastuzumab products compete, Herzuma alone surpassed the combined market share of all other products.
The autoimmune disease treatment segment is also showing strong growth. The flagship product Remsima and its subcutaneous injection formulation Remsima SC achieved a combined 58% market share in Australia, dominating the market. Remsima SC's market share surged from 5% in 2022 to 29% in just three years, showing an average annual growth rate of approximately 80%. The recently launched plaque psoriasis treatment Steqeyma also secured a 12% market share within one quarter.
These results stem from the combination of the local subsidiary's tailored sales strategy and Australia's biosimilar-friendly policies. While the Australian government requires separate approval procedures for prescribing original drugs, it grants simplified prescription codes for biosimilars, enhancing convenience for medical professionals. Celltrion actively leveraged this while focusing on building supply chains with major hospitals and pharmacy personnel.
In New Zealand, Celltrion's oncology portfolio dominates the market. Herzuma has virtually captured the market with nearly 100% share, while Vegzelma, a treatment for metastatic colorectal cancer, also holds an 81% share. Analysts attribute this success to smooth communication with Pharmac, New Zealand's government procurement agency, leading to continued tender wins.
Celltrion plans to sequentially launch new high-margin products such as osteoporosis treatments Stoboklo and Osenbelt to maximize marketing synergy. The strategy aims to leverage brand trust from existing products to facilitate early market entry for subsequent lineups and further strengthen its dominance in Oceania.
"We will do our best to achieve sustainable growth through localized sales strategies and strengthened marketing capabilities based on an expanded product portfolio," said Kim Ji-tae, Celltrion's Head of Southern Asia.
